Victoria Socha

DocwireNews

Hyperkalemia, defined as serum potassium level&nbsp; &gt;5 mEq/L, can lead to life-threatening arrhythmias and sudden cardiac death. In patients with cardiorenal syndrome, the care for hyperkalemia becomes significantly complex. There are few data on the economic impact of care for hyperkalemia in patients with cardiorenal syndrome.N.R. Desai, MD, MPH, and colleagues utilized real-word data to conduct a retrospective cohort study to examine the economic impact of hyperkalemia on patients with cardiorenal syndrome in Medicaid managed care population in the United States. Results of the study were reported in American Health &amp; Drug Benefits [2019;12(7):352-361].The study analyzed data from a Medicaid database from one state in southern United States. The data covered a 30-month period between 2013 and 2016. There total study cohort included 3563 patients; of those, 973 had hyperkalemia and 2590 did not have hyperkalemia (controls). Patients were matched based on age, comorbidities, and Medicaid eligibility status and duration. Inclusion criteria for patients in the hyperkalemia cohort were age &ge;18 years, Medicaid-only insurance status, coded cardiorenal diagnosis, and a claim for hyperkalemia during the study period. Costs were determined using paid claims data.Healthcare costs were reported as medical and pharmacy costs per member per year (PMPY). In the hyperkalemia group, mean healthcare costs were $56,002 compared with $23,653 in the control group. The cost differences were driven by medical costs accrued in the hyperkalemia and in the control cohorts ($49,648 PMPY and $18,399 PMPY, respectively). The two largest drivers of the medical cost variance were inpatient costs ($33,116 PMPY in the hyperkalemia cohort vs $10,629 PMPY in the control group), and dialysis costs ($2716 PMPY in the hyperkalemia group vs $810 PMPY in the control cohort). In the hyperkalemia group, the medical loss ratio was 552% compared with 260% for the control group. Both groups had revenue deficits to the health plan; the hyperkalemia cohort had double the medical loss ratio compared with the control cohort.In conclusion, the researchers said, &ldquo;The findings from this Medicaid managed care population suggest that hyperkalemia increases healthcare utilization and costs, which are primarily driven by the costs associated with inpatient care and dialysis. Our findings demonstrate that the Medicaid beneficiaries who have cardiorenal comorbidities accrue high costs to the Medicaid health plan, and these costs are even higher if a hyperkalemia diagnosis is present. The very high medical loss ratio for the hyperkalemia cohort in our analysis indicates that enhanced monitoring and management of patients with hyperkalemia should be considered.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Economic Impact of Hyperkalemia in a Managed Care Population

Hyperkalemia

Hyperkalemia, defined as serum potassium level  &gt;5 mEq/L, can lead to life-threatening arrhythmias and sudden cardiac death. In patients with cardiorenal syndrome, the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe